Hsiung Kuei-Ching, Chiang Huan-Jung, Reinig Sebastian, Shih Shin-Ru
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Graduate Institute of Biomedical Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Vaccines (Basel). 2024 Nov 28;12(12):1345. doi: 10.3390/vaccines12121345.
The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms' practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.
近年来,针对RNA病毒的疫苗研发进展迅速,尤其是在新冠疫情的推动下。本综述探讨了RNA病毒凭借其高突变率和人畜共患病潜力在促进疫苗创新方面所发挥的关键作用。我们还讨论了传统和现代疫苗平台以及人工智能等新技术对优化免疫策略的影响。本综述评估了各种疫苗平台,从传统方法(灭活疫苗和减毒活疫苗)到现代技术(亚单位疫苗、病毒和细菌载体、mRNA和DNA等核酸疫苗以及噬菌体样颗粒疫苗)。为了说明这些平台的实际应用,我们介绍了针对SARS-CoV-2、流感、寨卡和登革热等RNA病毒开发的疫苗的案例研究。此外,我们评估了人工智能在预测病毒突变和加强疫苗设计方面的作用。这些案例研究强调了基于RNA的疫苗的成功应用,特别是在抗击新冠疫情中,它挽救了数百万人的生命。目前针对流感、寨卡和登革热疫苗的临床试验继续显示出前景,突出了这些平台日益提高的效力和适应性。此外,人工智能正在推动疫苗候选物优化方面的改进,并为病毒进化提供预测模型,增强我们应对未来疫情爆发的能力。疫苗技术的进步,如针对SARS-CoV-2的mRNA疫苗的成功,凸显了核酸平台在对抗RNA病毒方面的潜力。正在进行的针对流感、寨卡和登革热的试验证明了平台的适应性,而人工智能通过预测病毒突变来加强疫苗设计。将这些创新与“同一健康”方法相结合,该方法将人类、动物和环境健康统一起来,对于加强全球对未来RNA病毒威胁的防范至关重要。